Luo Qiushi, Ma Xiaozhu, Mei Shuai, Wuyun Qidamugai, Zhou Li, Cai Ziyang, Wen Yi, Wang Shitao, Yan Jiangtao, Li Huaping, Fan Jiahui, Dai Meiyan
Division of Cardiology, Departments of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Wuhan 430030, China.
Biomedicines. 2025 Jun 25;13(7):1557. doi: 10.3390/biomedicines13071557.
: Diabetes significantly increases the risk of atrial fibrillation (AF), but identifying high-risk individuals remains a clinical challenge. This study aimed to improve AF risk stratification in diabetic patients through a combination of clinical modeling and untargeted metabolomic analysis. : A clinical risk score was developed using data from the National Health and Nutrition Examination Survey (NHANES) and validated in an independent cohort from Tongji Hospital. Its association with long-term outcomes and its ability to predict AF recurrence after catheter ablation were assessed in follow-up studies. Additionally, untargeted plasma metabolomics was performed in a subset of diabetic patients with and without AF to explore underlying mechanism. The risk score showed good predictive performance in both the development and validation cohorts and was significantly associated with clinical prognosis. When combined with left atrial diameter and AF type, it also improved the prediction of AF recurrence after ablation. Metabolomic profiling revealed notable disturbances in energy metabolism, heightened inflammatory activity, and elevated stress responses in AF patients, indicating a distinct metabolic risk profile. This study provided two approaches to identify high-risk AF in diabetic patients, discussed the underlying pathophysiological mechanisms, and compared their characteristics and applications. And integrated strategies could improve AF risk stratification and personalized management in the diabetic.
糖尿病显著增加心房颤动(AF)风险,但识别高危个体仍是一项临床挑战。本研究旨在通过临床建模与非靶向代谢组学分析相结合,改善糖尿病患者的房颤风险分层。使用来自美国国家健康与营养检查调查(NHANES)的数据开发了一种临床风险评分,并在同济医院的一个独立队列中进行了验证。在随访研究中评估了其与长期结局的关联以及预测导管消融术后房颤复发的能力。此外,对一部分有或无房颤的糖尿病患者进行了非靶向血浆代谢组学研究,以探索潜在机制。该风险评分在开发队列和验证队列中均显示出良好的预测性能,且与临床预后显著相关。当与左心房直径和房颤类型相结合时,它还改善了对消融术后房颤复发的预测。代谢组学分析揭示了房颤患者能量代谢的显著紊乱、炎症活性增强和应激反应升高,表明存在独特的代谢风险特征。本研究提供了两种识别糖尿病患者高危房颤的方法,讨论了潜在的病理生理机制,并比较了它们的特点和应用。综合策略可改善糖尿病患者的房颤风险分层和个性化管理。